Clinical Trials on EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance
Total 11 results
-
Blueprint Medicines CorporationActive, not recruitingNeoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditionsUnited States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
-
Blueprint Medicines CorporationTerminatedNeoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditionsUnited States
-
Sun Yat-sen UniversityRecruitingEGFR Tyrosine Kinase Inhibitors Plus VEGFR InhibitorsChina
-
Instituto Nacional de Cancerologia de MexicoUnknownEGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell AdenocarcinomaMexico
-
Hangzhou Cancer HospitalUnknownNon-small Cell Lung Cancer | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)China
-
Central Hospital, Nancy, FranceCompletedAdenocarcinoma of Lung Stage IV | Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, SomaticFrance
-
Tianjin Medical University Cancer Institute and...RecruitingCarcinoma, Non-Small-Cell Lung | EGF-R Positive Non-Small Cell Lung Cancer | Bevacizumab | Tyrosine Kinase InhibitorChina
-
Cancer Institute and Hospital, Chinese Academy...CompletedThe Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain MetastasesChina
-
Samsung Medical CenterActive, not recruitingNon-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase InhibitorsKorea, Republic of
-
Astellas Pharma Global Development, Inc.Approved for marketingAcute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) MutationsUnited States, Canada, Japan
-
University Health Network, TorontoNovartisCompletedChronic Phase Chronic Myeloid Leukemia | Philadelphia Positive Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myeloid Leukemia | Blastic Phase Chronic Myeloid Leukemia | Resistant to Tyrosine Kinase Inhibitor TherapyCanada